ALX Oncology swaps 13.35 million common shares for pre-funded warrants with stockholders
On October 14, 2026, ALX Oncology entered into exchange agreements under which certain stockholders surrendered 13,353,384 shares of common stock to the company in return for pre-funded warrants to buy the same number of shares. The exchange is expected to settle on or about October 15, 2026, and the filing does not state any cash proceeds to the company, so the change affects the form of the holdings rather than the company's cash position as described.
Key points
- Stockholders surrendered 13,353,384 common shares in exchange for pre-funded warrants for the same number of shares.
- Blackstone Annex Master Fund L.P. affiliates accounted for 12,885,891 shares; RA Capital Healthcare Fund, L.P. for 213,667 shares; venBio Global Strategic Fund, L.P. for 253,826 shares.
- Pre-funded warrants have an exercise price of $0.001 per share and are exercisable at any time, subject to 4.99% or 9.99% beneficial ownership limits.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.